VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of disease, today announced that Founder and CEO Tamer Mohamed will present at the 42nd Annual J.P. Morgan Healthcare Conference, held January 8-11, 2024 in San Francisco, CA.
The presentation will take place on Thursday, January 11, 2024, at 9:30 a.m. PT.
About Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. The company’s current therapeutic pipeline is focused on metabolic and endocrine diseases such as diabetes, obesity, and congenital liver disorders. Learn more at www.aspectbiosystems.com.
